Hemispherx Biopharma to Present At Fall 2006 Micro Cap Conference

Sept. 18, 2006--Hemispherx Biopharma, Inc. (AMEX HEB) today announced that William A. Carter, MD, Chairman & CEO, will present at the Fall 2006 Micro Cap Conference in New York City on Tuesday, September 19, at 10:30 AM EST. The Conference, sponsored by Friedland Capital, Inc., will be held at the Doubletree Suites Times Square, 1568 Broadway (47th Street & 7th Avenue).

Dr. Carter's presentation will recount the year-to-date achievements of Hemispherx Biopharma and the strategy going forward. The Company will continue to focus its efforts on three areas that have the greatest potential for revenue growth and corporate expansion.

1) Submitting the first new drug application (NDA) for the experimental drug Ampligen® for Chronic Fatigue Syndrome (CFS), one of the last severe chronic diseases without a recognized treatment. The Company is currently formulating a marketing strategy for potential distribution of Ampligen® for CFS.

2) The Company is also formulating a broad-spectrum biodefense strategy around the experimental agents Ampligen® and Alferon LDO (Low Dose Oral). The initial phase of this strategy is focused on avian and seasonal influenza.

3) Clinical efforts are focused to validate suggestions that Alferon N Injection®, already approved for HPV-related genital warts, may have application in vulvar vestibulitis syndrome (VVS), an HPV-related disease. VVS is an ailment affecting approximately 14% of the female population in the U.S. and can also be severely debilitating.

About Hemispherx

Hemispherx Biopharma, based in Philadelphia, is a biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of viral and immune-based disorders. Hemispherx Biopharma's flagship products include Alferon® and the experimental drugs Ampligen®, Alferon LDO and Oragens(TM). Alferon® is approved for a category of STD infection, and Ampligen® and Oragens(TM) represent experimental nucleic acids being developed for globally important diseases. Hemispherx's platform technology includes large and small agent components for potential treatment of various viral infections. Hemispherx has in excess of 100 patents comprising its core intellectual property estate, a fully commercialized product (Alferon® N) and GMP certified manufacturing facilities for its novel pharma products.